389 related articles for article (PubMed ID: 25436731)
21. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
[TBL] [Abstract][Full Text] [Related]
22. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Hughes KA; Webster SP; Walker BR
Expert Opin Investig Drugs; 2008 Apr; 17(4):481-96. PubMed ID: 18363514
[TBL] [Abstract][Full Text] [Related]
23. The expression of omental 11β-HSD1 is not increased in severely obese women with metabolic syndrome.
Michalaki M; Kyriazopoulou V; Antonacopoulou A; Koika V; Nikolaou M; Tsoukas A; Kalfarentzos F; Vagenakis AG; Voukelatou G; Papavassiliou AG
Obes Facts; 2012; 5(1):104-11. PubMed ID: 22433622
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients.
Baudrand R; Domínguez JM; Carvajal CA; Riquelme A; Campino C; Macchiavello S; Bozinovic M; Morales M; Pizarro M; Solis N; Escalona A; Boza C; Arrese M; Fardella CE
Metabolism; 2011 Dec; 60(12):1775-80. PubMed ID: 21704348
[TBL] [Abstract][Full Text] [Related]
25. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
Morton NM
Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
[TBL] [Abstract][Full Text] [Related]
26. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
Gathercole LL; Stewart PM
J Steroid Biochem Mol Biol; 2010 Oct; 122(1-3):21-7. PubMed ID: 20347978
[TBL] [Abstract][Full Text] [Related]
27. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
28. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Morgan SA; Tomlinson JW
Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593
[TBL] [Abstract][Full Text] [Related]
29. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
30. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
Jang C; Obeyesekere VR; Dilley RJ; Krozowski Z; Inder WJ; Alford FP
J Clin Endocrinol Metab; 2007 Aug; 92(8):3314-20. PubMed ID: 17519316
[TBL] [Abstract][Full Text] [Related]
31. Testosterone stimulates adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in a depot-specific manner in children.
Zhu L; Hou M; Sun B; Burén J; Zhang L; Yi J; Hernell O; Li X
J Clin Endocrinol Metab; 2010 Jul; 95(7):3300-8. PubMed ID: 20410225
[TBL] [Abstract][Full Text] [Related]
32. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
33. A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBPalpha independent.
Bruley C; Lyons V; Worsley AG; Wilde MD; Darlington GD; Morton NM; Seckl JR; Chapman KE
Endocrinology; 2006 Jun; 147(6):2879-85. PubMed ID: 16543369
[TBL] [Abstract][Full Text] [Related]
34. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
35. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome.
Loerz C; Maser E
J Steroid Biochem Mol Biol; 2017 Nov; 174():65-71. PubMed ID: 28765040
[TBL] [Abstract][Full Text] [Related]
36. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
Saiah E
Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
[TBL] [Abstract][Full Text] [Related]
37. Generation of porcine fibroblasts overexpressing 11β-HSD1 with adipose tissue-specific aP2 promoter as a porcine model of metabolic syndrome.
Jung EM; An BS; Kim YK; Jeong YH; Hwang WS; Jeung EB
Mol Med Rep; 2013 Sep; 8(3):751-6. PubMed ID: 23864280
[TBL] [Abstract][Full Text] [Related]
38. Expression and activity of the cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 is tissue and species-specific.
Dammann C; Stapelfeld C; Maser E
Chem Biol Interact; 2019 Apr; 303():57-61. PubMed ID: 30796905
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening.
Lagos CF; Vecchiola A; Allende F; Fuentes CA; Tichauer JE; Valdivia C; Solari S; Campino C; Tapia-Castillo A; Baudrand R; Villarroel P; Cifuentes M; Owen GI; Carvajal CA; Fardella CE
Mol Cell Endocrinol; 2014 Mar; 384(1-2):71-82. PubMed ID: 24447464
[TBL] [Abstract][Full Text] [Related]
40. Tissue-specific dysregulation of cortisol metabolism in human obesity.
Rask E; Olsson T; Söderberg S; Andrew R; Livingstone DE; Johnson O; Walker BR
J Clin Endocrinol Metab; 2001 Mar; 86(3):1418-21. PubMed ID: 11238541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
